Suppr超能文献

罕见的迟发性霉酚酸酯相关结肠炎。

Unusually late-onset mycophenolate mofetil-related colitis.

作者信息

Curtin Bryan F, Rachakonda Vikrant P, Von Rosenvinge Erik C

机构信息

Bryan F. Curtin, M.D., is Resident in Internal Medicine, Department of Internal Medicine; and Vikrant P. Rachakonda, M.D., Ph.D., is Fellow in Gastroenterology/Hepatology, Department of Internal Medicine, University of Maryland Medical Center, Baltimore. Erik C. von Rosenvinge, M.D., is Assistant Professor of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine and Department of Veterans Affairs Maryland Health Care System, Baltimore.

出版信息

Am J Health Syst Pharm. 2014 Nov 1;71(21):1858-61. doi: 10.2146/ajhp140085.

Abstract

PURPOSE

Serious gastrointestinal complications arising 13 years after the initiation of posttransplant immunosuppressant therapy with mycophenolate mofetil are reported.

SUMMARY

Over a three-month period, a male heart transplant recipient who had taken oral mycophenolate mofetil (2 g daily) for 13 years as part of an immunosuppressant maintenance regimen developed diarrhea and weight loss leading to renal failure and metabolic acidosis. There was no evidence of opportunistic infection, and immunostaining for cytomegalovirus yielded negative results. Colonoscopy revealed areas of congested, erythematous, and nodular mucosa. Histological examination of mucosal biopsy specimens revealed pathological abnormalities typical of those seen in cases of mycophenolate mofetil-associated colitis. On discontinuation of mycophenolate mofetil use, the patient's diarrhea resolved and his renal function improved. Colitis, diarrhea, and other gastrointestinal complications are commonly reported in patients receiving mycophenolate mofetil, an immunosuppressant widely used to prevent rejection of solid organ or bone marrow transplants; however, the onset of such symptoms after more than a decade of continuous use of the drug has not been previously reported. This case suggests that mycophenolate mofetil toxicity should be considered in the evaluation of late-onset posttransplant diarrhea regardless of the duration of therapy.

CONCLUSION

A 33-year-old man maintained on mycophenolate mofetil for 13 years after heart transplantation developed diarrhea, weight loss, and acute kidney injury over a three-month period. Colonoscopy and biopsy revealed pathological changes consistent with mycophenolate mofetil toxicity, and the patient's symptoms resolved after the drug was discontinued.

摘要

目的

报告在开始使用霉酚酸酯进行移植后免疫抑制治疗13年后出现的严重胃肠道并发症。

摘要

在三个月的时间里,一名男性心脏移植受者作为免疫抑制维持方案的一部分,口服霉酚酸酯(每日2克)达13年,出现腹泻和体重减轻,导致肾衰竭和代谢性酸中毒。没有机会性感染的证据,巨细胞病毒免疫染色结果为阴性。结肠镜检查显示黏膜有充血、红斑和结节状区域。黏膜活检标本的组织学检查显示出霉酚酸酯相关性结肠炎病例中典型的病理异常。停用霉酚酸酯后,患者的腹泻症状消失,肾功能得到改善。接受霉酚酸酯治疗的患者中,结肠炎、腹泻和其他胃肠道并发症较为常见,霉酚酸酯是一种广泛用于预防实体器官或骨髓移植排斥反应的免疫抑制剂;然而,此前尚未有过在连续使用该药物十多年后出现此类症状的报道。该病例表明,在评估移植后迟发性腹泻时,无论治疗时间长短,都应考虑霉酚酸酯毒性。

结论

一名33岁男性在心脏移植后使用霉酚酸酯维持治疗13年,在三个月内出现腹泻、体重减轻和急性肾损伤。结肠镜检查和活检显示与霉酚酸酯毒性一致的病理变化,停药后患者症状消失。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验